Dealing with Diabetes2 and remembering Goldi Community Group
A support group for individuals with Type2 diabetes. Encouragement, empathy, advice, and personal experiences from members dealing with the illness. A friendly environment with compassion and support as our main objective.
Diabetes jab gives new hope and can even help sufferers lose weight
A SIMPLE once-a-day jab could be a lifeline for at least 1.5 million diabetes patients, not only helping control their condition but also fighting obesity.
By: Jo WileyPublished: Wed, May 1, 2013
6Comments
The new jab could be a lifeline for at least 1.5million patients
The £1.90-a-day breakthrough treatment is far cheaper than using other similar drugs and could save the NHS at least £70million over the next five years.
Doctors can prescribe Lyxumia to patients from today following approval by the European Medicines Agency. They have hailed the treatment as a major new tool in the arsenal to tackle the growing problem of Type 2 diabetes.
It works in tandem with insulin to regulate glucose levels in the body in patients who cannot keep this controlled with insulin alone.
Professor Anthony Barnett, Emeritus Professor of Medicine at the University of Birmingham, warned: “Eventually this disease is going to bankrupt the NHS if we don’t do something about it.” By getting blood glucose under control “we can actually help patients dramatically reduce the risk of long-term horrendous complications”. Although many diabetes patients can control their condition with a good diet and healthy lifestyle, it is a progressive disease and if blood glucose remains uncontrolled it can lead to serious complications such as heart attack, amputation and early death.
In order to keep their diabetes under control, many patients have to inject themselves with insulin several times a day to keep their blood sugar level steady.
Trials have shown that around 100,000 patients treated with insulin alone have glucose levels way over target.
A third of those could be helped with Lyxumia, which works by specifically reducing after-meal glucose as well as complementing the reduction in before-meal levels from the insulin. It has an added benefit of helping patients lose weight by preventing the body from storing glucose in fat.
Professor Barnett, who is also a consultant physician at the Heart of England NHS Foundation Trust, said: “This is a very welcome new treatment option, particularly for those patients with Type 2 diabetes currently inadequately controlled on insulin.
“Early and aggressive treatment is critical. The launch of Lyxumia, which is a highly effective treatment for Type 2 diabetes, is an important part of an evolution of therapies which may help to combat the potentially devastating consequences of this important disease.
“This combination looks fantastic and this extra benefit is mainly due to this very profound reduction in post meal glucose. Diabetes is a progressive disease so we need more treatments. Single insulin is not sufficient for every patient. How best to manage these patients is to get blood glucose under control.”
Simon O’Neill, of Diabetes UK, said: “We welcome any new drug that gives more choice to patients and clinicians to help manage diabetes, which is a serious condition that unless properly managed can lead to devastating complications.”
Nearly four million people's lives are blighted by diabetes
Early and aggressive treatment is critical
Professor Barnett
The new treatment is much cheaper than others – around £54 for a 28-day supply compared to £73.
This means that for every 100 patients, a further 33 can be treated for the same cost.
It has also been shown to dramatically cut the chance of patients suffering a dangerous attack which is estimated to cost the UK at least £72.2million a year.
Nearly four million people’s lives are blighted by diabetes.
Type 2 is caused by obesity and an unhealthy lifestyle.
Related articles
Diet ‘just as good as op’ for diabetes
I found out I had diabetes at the dentist
Health MoTs to beat diabetes
Diabetes warning over soft drinks
Share this Print
A SIMPLE once-a-day jab could be a lifeline for at least 1.5 million diabetes patients, not only helping control their condition but also fighting obesity.
By: Jo WileyPublished: Wed, May 1, 2013
6Comments
The new jab could be a lifeline for at least 1.5million patients
The £1.90-a-day breakthrough treatment is far cheaper than using other similar drugs and could save the NHS at least £70million over the next five years.
Doctors can prescribe Lyxumia to patients from today following approval by the European Medicines Agency. They have hailed the treatment as a major new tool in the arsenal to tackle the growing problem of Type 2 diabetes.
It works in tandem with insulin to regulate glucose levels in the body in patients who cannot keep this controlled with insulin alone.
Professor Anthony Barnett, Emeritus Professor of Medicine at the University of Birmingham, warned: “Eventually this disease is going to bankrupt the NHS if we don’t do something about it.” By getting blood glucose under control “we can actually help patients dramatically reduce the risk of long-term horrendous complications”. Although many diabetes patients can control their condition with a good diet and healthy lifestyle, it is a progressive disease and if blood glucose remains uncontrolled it can lead to serious complications such as heart attack, amputation and early death.
In order to keep their diabetes under control, many patients have to inject themselves with insulin several times a day to keep their blood sugar level steady.
Trials have shown that around 100,000 patients treated with insulin alone have glucose levels way over target.
A third of those could be helped with Lyxumia, which works by specifically reducing after-meal glucose as well as complementing the reduction in before-meal levels from the insulin. It has an added benefit of helping patients lose weight by preventing the body from storing glucose in fat.
Professor Barnett, who is also a consultant physician at the Heart of England NHS Foundation Trust, said: “This is a very welcome new treatment option, particularly for those patients with Type 2 diabetes currently inadequately controlled on insulin.
“Early and aggressive treatment is critical. The launch of Lyxumia, which is a highly effective treatment for Type 2 diabetes, is an important part of an evolution of therapies which may help to combat the potentially devastating consequences of this important disease.
“This combination looks fantastic and this extra benefit is mainly due to this very profound reduction in post meal glucose. Diabetes is a progressive disease so we need more treatments. Single insulin is not sufficient for every patient. How best to manage these patients is to get blood glucose under control.”
Simon O’Neill, of Diabetes UK, said: “We welcome any new drug that gives more choice to patients and clinicians to help manage diabetes, which is a serious condition that unless properly managed can lead to devastating complications.”
Nearly four million people's lives are blighted by diabetes
Early and aggressive treatment is critical
Professor Barnett
The new treatment is much cheaper than others – around £54 for a 28-day supply compared to £73.
This means that for every 100 patients, a further 33 can be treated for the same cost.
It has also been shown to dramatically cut the chance of patients suffering a dangerous attack which is estimated to cost the UK at least £72.2million a year.
Nearly four million people’s lives are blighted by diabetes.
Type 2 is caused by obesity and an unhealthy lifestyle.
Related articles
Diet ‘just as good as op’ for diabetes
I found out I had diabetes at the dentist
Health MoTs to beat diabetes
Diabetes warning over soft drinks
Share this Print
and then you see some obscure artilce saying it was pulled for some reason
like all the books you see online written by someone who claims to have cured diabetes
or cancer, flu etc etc.
All Balony on Rye